Nicox Extends Cash Runway to Q1 2028 Ahead of NCX 470 PDUFA Date

Nicox SA's ability to sustain operations through a critical FDA review cycle hinges on a sequenced financial structure that QA and regulatory affairs leads at small ophthalmology sponsors will recognise as a familiar pre-approval pressure point. The company reported estimated cash and cash equivalents of €8.4 million as of 31 August 2026, up from €4.1 million at year-end 2025, sufficient to fund existing operations beyond Q1 2028.

The primary variable in that timeline is the PDUFA date of 30 April 2027 for NCX 470, a nitric oxide-donating prostaglandin analogue for glaucoma under NDA review in the United States. Receipt of the approval milestone payment from exclusive U.S. partner Kowa would extend the runway into 2029. Royalty income following an anticipated H2 2027 commercial launch could extend visibility further still, though both outcomes remain contingent on regulatory clearance.

For regulatory affairs teams tracking PDUFA cycles, the structure illustrates how pre-commercialisation planning and cash management converge during the NDA review period. Nicox has reduced fixed costs materially and retains access to additional financing under a Vester Finance shareholder loan facility announced in June 2026, providing a secondary buffer if review timelines shift or assumptions around income and costs change.

A leadership adjustment within the development function is also relevant to teams monitoring NDA continuity. Doug Hubatsch, EVP and Chief Scientific Officer since December 2021, has transitioned to a Chief Scientific Advisor role, stepping back from operational management while remaining engaged through the review period. Siobhan Garbutt, VP and Head of Clinical Development, assumes leadership of the development team. Garbutt has been with Nicox since July 2022, led NCX 470 clinical activities, and contributed substantially to writing the NDA, bringing close to 20 years of ophthalmology-focused clinical development experience across large pharma, biotech, and CRO environments.

The transition preserves institutional knowledge at the NDA interface while repositioning senior scientific resource toward business development evaluation, including potential collaborations or business combinations that management is actively assessing.

The 30 April 2027 PDUFA date now represents the most consequential near-term checkpoint for Nicox's operational continuity and its partners' pre-commercialisation readiness.

Source: Nicox SA via GlobeNewswire, 2 September 2026.